Transit Scientific’s XO Score Scoring Sheath Platform Wins Medical Design Award
May 28, 2021
Transit Scientific”s XO Score Scoring Sheath Platform has been named a winner in the 2021 Medical Design Excellence Awards (MDEA). The MDEA is a premier design competition in the medtech industry, recognizing significant achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility.
Recently, the company received European CE Mark clearance for the XO Score.
“We are honored that our XO Score Platform has been recognized by the MDEA organization,” said Greg Method, President of Transit Scientific in Park City, Utah. “We designed XO Score as a novel way to expand angioplasty-based tools available to physicians for treatment of Peripheral Artery Disease (PAD), Critical Limb Ischemia (CLI), and End Stage Renal Disease (ESRD). The award is a testament to the dedication and hard work of the team at Transit Scientific and reflects our commitment to bringing new technologies to market for the advancement of patient care.”
“BioUtah congrratulates Transit Scientific on this well-deserved award,” said Kelvyn Cullimore,president and CEO of BioUtah. “The recognition mirrors the company’s talented team and cuting-edge innovation. We’re proud of this BioHive trailblazer.”
XO Score is a novel scoring sheath that works by fitting over physician selected off-the-shelf PTA balloons to enable scoring and cutting vessel preparation. The unique balloon expandable scoring element enables a single XO Score device to work with a large range of balloon diameters and lengths for in-procedure adaptability. XO Score has been used successfully to dilate calcified and fibrous lesions during a multi-site, multi-user limited market release.
The device is currently indicated for treatment of peripheral vascular stenosis including hemodialysis fistulas and grafts.
Recent News
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
- KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging
- Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
- Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
- Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial
- Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology